Nektar Therapeutics (NKTR) EBT Margin (2010 - 2026)
Nektar Therapeutics' (NKTR) quarterly EBT Margin came in at 396.74% in Q1 2026, up 4656.0% year-on-year from 8.34% in Q1 2025, and down 149.31% quarter-over-quarter from 159.13% in Q4 2025.
Nektar Therapeutics (NKTR) EBT Margin (2010 - 2026) Analysis & Trends
Nektar Therapeutics' EBT Margin history runs 17 years deep, the most recent figure standing at 396.74% for Q1 2026.
- On a quarterly basis, EBT Margin rose 4656.0% year-over-year to 396.74% in Q1 2026; TTM through Mar 2026 was 273.59%, a 12605.0% decrease from a year earlier, with the FY2025 full-year figure at 281.52%, down 16041.0% from the prior year.
- EBT Margin eased to 396.74% in Q1 2026 per NKTR's latest filing, from 159.13% in the prior quarter.
- Across five years, EBT Margin topped out at 24.0% in Q4 2024 and bottomed at 736.47% in Q2 2022.
- The 5-year median for EBT Margin is 250.6% (2022), against an average of 295.86%.
- Across the five-year window, EBT Margin tumbled 177137 bps in 2022 and soared 48686 bps in 2023, its largest moves.
- Year by year, EBT Margin stood at 256.75% in 2022, then soared by 31 bps to 176.29% in 2023, then surged by 114 bps to 24.0% in 2024, then slumped by 763 bps to 159.13% in 2025, then plunged by 149 bps to 396.74% in 2026.
- Per Business Quant, the three latest NKTR EBT Margin figures stand at 396.74% (Q1 2026), 159.13% (Q4 2025), and 297.04% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 17.13% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 41.95% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 23.05% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 34.77% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Nektar Therapeutics | 2.04 Bn | 1.48 Bn | 3.16 Mn | -396.74% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -396.74% |
| Dec 31, 2025 | -159.13% |
| Sep 30, 2025 | -297.04% |
| Jun 30, 2025 | -352.53% |
| Mar 31, 2025 | -443.30% |
| Dec 31, 2024 | 24.00% |
| Sep 30, 2024 | -153.57% |
| Jun 30, 2024 | -222.73% |
| Mar 31, 2024 | -170.23% |
| Dec 31, 2023 | -176.29% |
| Sep 30, 2023 | -190.10% |
| Jun 30, 2023 | -249.62% |
| Mar 31, 2023 | -634.81% |
| Dec 31, 2022 | -256.75% |
| Sep 30, 2022 | -250.60% |
| Jun 30, 2022 | -736.47% |
| Mar 31, 2022 | -363.66% |
| Dec 31, 2021 | 1,514.62% |
| Sep 30, 2021 | -520.02% |
| Jun 30, 2021 | -441.80% |